Why the study?
Does intravenous nifekalant terminate arrhythmias and prevent recurrence in patients with life-threatening refractory ventricular tachyarrhythmias?
Does intravenous nifekalant terminate arrhythmias and prevent recurrence in patients with life-threatening refractory ventricular tachyarrhythmias?
Nifekalant is an effective emergency treatment for terminating and preventing recurrence of life-threatening refractory ventricular tachyarrhythmias, though careful QT monitoring is required.
Answers are grounded in this paper and cite their sources.
May support nifekalant consideration for refractory VT/VF with QT caution; leaves open randomized confirmation of efficacy.
BACKGROUND: Because class I anti-arrhythmic drugs sometimes suppress cardiac function caused by their negative inotropic effects, they are not adequate for use in patients with severe heart failure, even as emergency treatment for life-threatening ventricular tachyarrhythmias (ventricular tachycardia (VT)/ventricular fibrillation (VF)). METHODS AND RESULTS: An objective evaluation committee re-evaluated the effect of nifekalant in 191 patients with refractory VT/VF. The attack termination was achieved in 45 out of 93 patients (48.4%). Nifekalant was administered to 39 patients with direct-current (DC) shock-resistant VT/VF and directly terminated VT/VF in 9 patients. In 15 of the remaining 29 patients (51.7%), VT/VF was successfully cardioverted by additional DC shock after nifekalant administration. Prevention of recurrence was achieved in 60 out of 99 patients (60.6%). Corrected QT interval (QTc) was significantly prolonged after initial administration of nifekalant (0.463+/-0.056 to 0.504 +/-0.072), and during maintenance infusion (0.470 +/-0.056 to 0.547+/-0.070). As an adverse reaction, excess prolongation of QTc was noted in 11 patients including 3 patients with torsades de pointes. Hemodynamic parameters tended to improve after maintenance infusion of nifekalant. CONCLUSION: Nifekalant is effective and useful for life-threatening refractory ventricular tachyarrhythmias, although careful observation of the QT interval is required.
No takes yet. Share an insight, caveat, or question.
Katoh et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: